Oracle Corporation (ORCL)
Pre-Market:
| Previous Close | 113.75 |
| Open | 113.91 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 113.65 - 116.76 |
| 52 Week Range | 94.41 - 132.77 |
| Volume | |
| Avg. Volume | 8,491,550 |
| Market Cap | 315.062B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | 30.25 |
| EPS (TTM) | 3.79 |
| Earnings Date | Jun 10, 2024 - Jun 14, 2024 |
| Forward Dividend & Yield | 1.60 (1.40%) |
| Ex-Dividend Date | Apr 09, 2024 |
| 1y Target Est | 140.07 |
Insider MonkeyTop 20 Tech Companies in Silicon Valley
In this piece, we will take a look at the top 20 technology companies in Silicon Valley. If you want to skip our coverage of the world’s technology hub and a region that has changed the world as we know it, then check out 5 Top Tech Companies in Silicon Valley. If there’s one thing […]
Simply Wall St.Returns At Oracle (NYSE:ORCL) Appear To Be Weighed Down
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
PR NewswireOracle Advances Global RTSM Capabilities to Help Sponsors
6th Clinical Trial Supply Forum -- Helping sponsors and CROs meet the challenges of complex and global clinical trial studies, Oracle today announced new capabilities in Oracle Clinical One Randomization and Trial Supply Management (RTSM). With new enhancements for use, access, and regionalization, Clinical One RTSM users can address dynamic, country-specific regulations and requirements, and gain speed, reliability, and transparency of trials from commencement to closeout.
